Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

(1) Background: recent evidence suggests that long low-dose capecitabine regimens have a synergistic effect with endocrine therapy as aromatase inhibitors (AIs), and might increase overall survival for hormone-receptor-positive, HER2-negative, metastatic breast cancer compared to both treatments. We...

Full description

Bibliographic Details
Main Authors: Alberto Alvarado-Miranda, Fernando Ulises Lara-Medina, Wendy R. Muñoz-Montaño, Juan W. Zinser-Sierra, Paula Anel Cabrera Galeana, Cynthia Villarreal Garza, Daniel Sanchez Benitez, Jesús Alberto Limón Rodríguez, Claudia Haydee Arce Salinas, Alberto Guijosa, Oscar Arrieta
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Current Oncology
Subjects:
aromatase inhibitor
capecitabine
metastatic breast cancer
metronomic chemotherapy
combined therapy
Online Access:https://www.mdpi.com/1718-7729/30/7/454

Internet

https://www.mdpi.com/1718-7729/30/7/454

Similar Items